Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
ITRACONAZOLE
Janssen Cilag Ltd.
QJ02AC02
10 Mg/Ml
Oral Solution
Antifungal
Feline
2004-11-19
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Itrafungol 10 mg/ml Oral Solution. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 3 PHARMACEUTICAL FORM Oral solution. Yellow to slightly amber, clear solution. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Cats. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Treatment of dermatophytosis caused by _Microsporum canis._ 4.3 CONTRAINDICATIONS Do not administer to cats with hypersensitivity to itraconazole or one of the other ingredients. Do not administer to cats with impaired liver or kidney function. For use in pregnant and lactating queens: see section 4.7 ACTIVE SUBSTANCES MG/ML Intraconazole 10 EXCIPIENTS: Caramel (E150) 0.2 Propylene glycol (E1520) 103.6 Sorbitol 70% Non-crystallising Solution 245.1 For a full list of excipients, see section 6.1 IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 30/08/2011_ _CRN 7010918_ _page number: 1_ 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES Some cases of feline dermatophytosis can be difficult to cure, especially in catteries. Cats treated with itraconazole can still infect other cats with _M. canis _as long as they are not mycologically cured. It is therefore advised to minimise the risk of re-infection or spread of infection by keeping healthy animals (including dogs as they can also be infected by _M. canis_) separate from cats that are being treated. Cleaning and disinfection of the environment with appropriate fungicidal products is highly recommended – especially in case of group problems. When clipping the hair of infected cats, the advice of the veterinarian should be sought first. Clipping of the hair coat is considered useful because it removes infected hairs, stimulates Read the complete document